By Fineline Cube 
US-based biopharma Amgen Inc. (NASDAQ: AMGN) released its Q2 2025 financial results, showing a 9% year-on-year (YOY) increase in revenue to USD 9.2 billion. Sales volume grew by 13%, partially offset by a 3% negative impact from pricing pressure.
Key Product Performance
Fifteen brands delivered double-digit growth during the quarter. Highlights include:
- Repatha (evolocumab): 31% YOY growth to USD 696 million.
- Evenity (romosozumab): 32% increase to USD 518 million.
- Rare Disease Portfolio:
- Tepezza (teprotumumab): +5% to USD 505 million.
- Krystexxa (pegloticase): +19% to USD 349 million.
- Uplizna (inebilizumab): +91% to USD 176 million.
- Inflammatory Portfolio:
- Tezspire (tezepelumab): +46% to USD 342 million.
- Otezla (apremilast): +14% to USD 618 million.
- Oncology Portfolio:
- Blincyto (blinatumomab): +45% to USD 384 million.
Growth Challenges
- Enbrel (etanercept): Sales declined by 34% YOY to USD 604 million due to price reductions linked to the US Medicare Part D redesign.
- Denosumab Biosimilar Impact: Sales of Prolia decreased by 4% to USD 1.1 billion, and Xgeva by 5% to USD 532 million. Further erosion is anticipated in the second half of the year with three biosimilars now on the market.-Fineline Info & Tech